Renalytix and Quest Diagnostics partner to expand kidneyintelX.dkd testing across the US

Renalytix has signed a multi-year agreement with Quest Diagnostics to expand US access to its kidneyintelX.dkd blood test for patients with type 2 diabetes and chronic kidney disease.

The collaboration is designed to make kidneyintelX.dkd accessible through Quest's national diagnostics network, broadening physician access to a test that assesses risk of progressive kidney-function decline.

kidneyintelX.dkd is FDA-authorised and Medicare-reimbursed, supporting its use in identifying higher-risk patients who may benefit from earlier intervention and more intensive disease management.

Field	Content
Alert Type	Industry Update
Companies	Renalytix; Quest Diagnostics
Agreement Type	Multi-year diagnostics collaboration
Product	kidneyintelX.dkd
Therapy Area	Chronic kidney disease; type 2 diabetes
Technology or Modality	Blood-based prognostic diagnostic test
Geography	United States
What Happened	Renalytix signed a multi-year agreement with Quest Diagnostics to expand access to kidneyintelX.dkd through Quest's US diagnostics network.
Why It Matters	Quest's national reach could materially increase physician and patient access to kidneyintelX.dkd.
Supporting Context	The test is FDA-authorised and Medicare-reimbursed for assessing risk of progressive kidney-function decline in adults with type 2 diabetes and early-stage chronic kidney disease.
Potential Impact	Broader access could support earlier risk stratification and more targeted intervention for patients at increased risk of kidney disease progression.
Key Takeaway	Renalytix is partnering with Quest Diagnostics to expand US access to kidneyintelX.dkd.
What to Watch	Commercial rollout through Quest and subsequent adoption by physicians and health systems.
Primary Source	Renalytix
Relevant Date	1 September 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector

• Contact us on: support@nuaxia.com